Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 8,851 Shares of Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 8,851 shares of the stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $27.53, for a total value of $243,668.03. Following the transaction, the insider now directly owns 75,931 shares in the company, valued at approximately $2,090,380.43. The transaction was disclosed in a filing with the SEC, which is available at this link.

Catriona Yale also recently made the following trade(s):

• On Monday, August 26th, Catriona Yale sold 5,200 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.51, for a total transaction of $143,052.00.
• On Tuesday, June 11th, Catriona Yale sold 2,825 shares of Akero Therapeutics stock. The shares were sold at an average price of $22.64, for a total transaction of $63,958.00.

Akero Therapeutics Price Performance

Shares of NASDAQ AKRO opened at $26.89 on Friday. Akero Therapeutics, Inc. has a fifty-two week low of $11.25 and a fifty-two week high of $53.77. The company has a debt-to-equity ratio of 0.04, a quick ratio of 30.12 and a current ratio of 30.12. The company has a market cap of $1.86 billion, a PE ratio of -8.40 and a beta of -0.28. The business has a 50-day simple moving average of $25.11 and a two-hundred day simple moving average of $23.66.

Akero Therapeutics (NASDAQ:AKRO) last released its earnings results on Friday, August 9th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.09. As a group, equities analysts expect that Akero Therapeutics, Inc. will post -3.82 EPS for the current fiscal year.

Analyst Ratings Changes

AKRO has been the topic of several recent research reports. Evercore ISI dropped their target price on Akero Therapeutics from $50.00 to $38.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 15th. Wolfe Research assumed coverage on Akero Therapeutics in a research report on Tuesday, June 11th. They set an “outperform” rating on the stock. Canaccord Genuity Group reduced their target price on shares of Akero Therapeutics from $59.00 to $56.00 and set a “buy” rating for the company in a report on Monday, May 13th. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Akero Therapeutics in a report on Monday, August 12th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Akero Therapeutics in a research note on Thursday, June 20th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $41.13.

Institutional Investors Weigh In On Akero Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. abrdn plc acquired a new position in shares of Akero Therapeutics in the 4th quarter valued at $1,671,000. Wellington Management Group LLP grew its stake in Akero Therapeutics by 247.7% during the 4th quarter. Wellington Management Group LLP now owns 2,881,989 shares of the company’s stock valued at $67,294,000 after purchasing an additional 2,053,028 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Akero Therapeutics by 19.0% in the first quarter. Vanguard Group Inc. now owns 3,669,923 shares of the company’s stock valued at $92,702,000 after purchasing an additional 584,875 shares during the period. Capstone Investment Advisors LLC purchased a new position in shares of Akero Therapeutics in the first quarter worth about $2,205,000. Finally, Seven Eight Capital LP acquired a new stake in shares of Akero Therapeutics during the fourth quarter worth about $1,459,000.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.